Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $33.7 million.

  • Kiniksa Pharmaceuticals International's Cash from Operations rose 160612.7% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.9 million, marking a year-over-year increase of 81480.79%. This contributed to the annual value of $25.7 million for FY2024, which is 9313.59% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Cash from Operations is $33.7 million, which was up 160612.7% from $28.1 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Cash from Operations registered a high of $62.1 million during Q3 2022, and its lowest value of -$40.1 million during Q1 2021.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Cash from Operations value was -$2.2 million (recorded in 2024), while the average stood at $136315.8.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Cash from Operations tumbled by 11316.38% in 2024 and then surged by 160612.7% in 2025.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Cash from Operations stood at -$18.9 million in 2021, then soared by 38.7% to -$11.6 million in 2022, then surged by 137.36% to $4.3 million in 2023, then skyrocketed by 333.99% to $18.8 million in 2024, then skyrocketed by 79.42% to $33.7 million in 2025.
  • Its last three reported values are $33.7 million in Q3 2025, $28.1 million for Q2 2025, and $22.3 million during Q1 2025.